A498
|
IC50 |
8456 nM
Compound: Cabozantinib
|
Antiproliferative activity against human A498 cells after 48 hrs by MTT assay
Antiproliferative activity against human A498 cells after 48 hrs by MTT assay
|
[PMID: 29057042]
|
A549
|
IC50 |
≥ 50 nM
Compound: Cabozantinib
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30248654]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells expressing c-Met after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells expressing c-Met after 48 hrs by MTT assay
|
[PMID: 35227978]
|
A549
|
IC50 |
0.76 μM
Compound: 1; XL-184
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33601310]
|
A549
|
IC50 |
15.23 μM
Compound: Cabozantinib
|
Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 34186178]
|
A549
|
IC50 |
3.75 μM
Compound: Cabozantinib
|
Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
|
[PMID: 31757525]
|
A549
|
IC50 |
4205 nM
Compound: Cabozantinib
|
Growth inhibition of human A549 cells incubated for 72 hrs by CCK8 assay
Growth inhibition of human A549 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 28651979]
|
A549
|
IC50 |
7.21 μM
Compound: Cabozantinib
|
Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay
Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33045329]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 32738414]
|
A549
|
IC50 |
8.5 μM
Compound: Cabozantinib
|
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 30940564]
|
A549
|
IC50 |
9.52 μM
Compound: Cabozantinib
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30503936]
|
A549/CDDP
|
IC50 |
19.6 μM
Compound: Cabozantinib
|
Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay
Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay
|
[PMID: 30503936]
|
BaF3
|
GI50 |
> 10 μM
Compound: Cabozantinib
|
Cytotoxicity against mouse BA/F3 cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay
Cytotoxicity against mouse BA/F3 cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay
|
[PMID: 27814560]
|
BaF3
|
GI50 |
0.01 μM
Compound: Cabozantinib
|
Inhibition of TEL-fused Ret S891A mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Inhibition of TEL-fused Ret S891A mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26652860]
|
BaF3
|
IC50 |
0.0219 μM
Compound: Cabozantinib
|
Antiproliferative activity against mouse BA/F3 cells expressing TPR-Met after 72 hrs by CCK8 assay
Antiproliferative activity against mouse BA/F3 cells expressing TPR-Met after 72 hrs by CCK8 assay
|
[PMID: 27068889]
|
BaF3
|
IC50 |
0.024 μM
Compound: Cabozantinib
|
Antiproliferative activity against mouse BAF3 cells harboring TRP-MET after 72 hrs by CCK-8 assay
Antiproliferative activity against mouse BAF3 cells harboring TRP-MET after 72 hrs by CCK-8 assay
|
[PMID: 29146452]
|
BaF3
|
GI50 |
0.05 μM
Compound: Cabozantinib
|
Inhibition of wild type TEL-fused RET (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Inhibition of wild type TEL-fused RET (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26652860]
|
BaF3
|
GI50 |
0.15 μM
Compound: Cabozantinib
|
Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
|
[PMID: 29133048]
|
BaF3
|
IC50 |
|
Inhibition of RET V804M mutant (unknown origin)expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay
Inhibition of RET V804M mutant (unknown origin)expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay
|
[PMID: 32292556]
|
BaF3
|
GI50 |
0.89 μM
Compound: Cabozantinib
|
Inhibition of TEL-fused Ret V804M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Inhibition of TEL-fused Ret V804M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26652860]
|
BaF3
|
GI50 |
0.91 μM
Compound: Cabozantinib
|
Inhibition of TEL-fused Ret V804L mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Inhibition of TEL-fused Ret V804L mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26652860]
|
BaF3
|
GI50 |
1.45 μM
Compound: Cabozantinib
|
Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
|
[PMID: 29133048]
|
BaF3
|
GI50 |
1.53 μM
Compound: Cabozantinib
|
Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
|
[PMID: 29133048]
|
BaF3
|
IC50 |
|
Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
|
[PMID: 26874741]
|
BaF3
|
IC50 |
|
Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
|
[PMID: 26874741]
|
BaF3
|
GI50 |
2.8 μM
Compound: Cabozantinib
|
Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
|
[PMID: 29133048]
|
BaF3
|
IC50 |
7.5 μM
Compound: XL184; BMS-907351
|
Inhibition of FLT3 (unknown origin) phosphorylation transfected in mouse BAF3 cells incubated for 1 to 3 hrs
Inhibition of FLT3 (unknown origin) phosphorylation transfected in mouse BAF3 cells incubated for 1 to 3 hrs
|
[PMID: 26717201]
|
BaF3
|
GI50 |
7.914 μM
Compound: Cabozantinib
|
Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay
Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay
|
[PMID: 32882611]
|
BaF3
|
IC50 |
889 nM
Compound: Cabozantinib
|
Inhibition of CCDC6-RET (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by SRB/CCK-8 assay
Inhibition of CCDC6-RET (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by SRB/CCK-8 assay
|
[PMID: 27131066]
|
BaF3
|
GI50 |
9.36 μM
Compound: Cabozantinib
|
Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
|
[PMID: 29133048]
|
CAKI-1
|
IC50 |
1.66 μM
Compound: Cabozantinib
|
Cytotoxicity against human CAKI-1 cells assessed as reduction cell viability by MTT assay
Cytotoxicity against human CAKI-1 cells assessed as reduction cell viability by MTT assay
|
[PMID: 34175535]
|
EBC-1
|
IC50 |
4.8 nM
Compound: Cabozantinib
|
Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
|
[PMID: 30248654]
|
EBC-1
|
IC50 |
51.4 nM
Compound: Cabozantinib
|
Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
|
[PMID: 28412159]
|
FHC
|
IC50 |
4.4 μM
Compound: Cabozantinib
|
Cytotoxicity against human FHC cells after 72 hrs by MTT assay
Cytotoxicity against human FHC cells after 72 hrs by MTT assay
|
[PMID: 30503936]
|
HCT-116
|
IC50 |
3.78 μM
Compound: Cabozantinib
|
Cytotoxicity against human HCT-116 cells assessed as reduction cell viability by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction cell viability by MTT assay
|
[PMID: 34175535]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 32738414]
|
HEK293
|
IC50 |
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33214822]
|
HeLa
|
IC50 |
> 10000 nM
Compound: XL184
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31382120]
|
HeLa
|
IC50 |
> 20 μM
Compound: Cabozantinib
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31307762]
|
HeLa
|
IC50 |
0.32 μM
Compound: 1; XL-184
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33601310]
|
HeLa
|
IC50 |
79.06 μM
Compound: XL-184
|
Antiproliferative activity against human HeLa cells expressing c-Met after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells expressing c-Met after 48 hrs by MTT assay
|
[PMID: 35227978]
|
HepG2
|
IC50 |
12 nM
Compound: Cabozantinib
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 28412159]
|
HepG2
|
IC50 |
15.58 μM
Compound: Cabozantinib
|
Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 34186178]
|
HepG2
|
IC50 |
3.05 μM
Compound: Cabozantinib
|
Cytotoxicity against human HepG2 cells assessed as reduction cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction cell viability by MTT assay
|
[PMID: 34175535]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33214822]
|
HL-60
|
IC50 |
22.46 μM
Compound: Cabozantinib
|
Antiproliferative activity against human HL60 cells harboring wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HL60 cells harboring wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 31466809]
|
HT-29
|
IC50 |
10.6 μM
Compound: Cabozantinib
|
Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay
|
[PMID: 32731184]
|
HT-29
|
IC50 |
11.5 μM
Compound: Cabozantinib
|
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 30503936]
|
HT-29
|
IC50 |
4.56 μM
Compound: Cabozantinib
|
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
|
[PMID: 31757525]
|
HT-29
|
IC50 |
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32113049]
|
HT-29
|
IC50 |
9.6 μM
Compound: Cabozantinib
|
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31307762]
|
HT-29
|
IC50 |
9.6 μM
Compound: Cabozantinib
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 30940564]
|
Huh-7
|
IC50 |
4348 nM
Compound: Cabozantinib
|
Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay
Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay
|
[PMID: 29057042]
|
HUVEC
|
IC50 |
45 nM
Compound: Cabozantinib
|
Cytotoxicity against HUVEC after 96 hrs by MTT assay
Cytotoxicity against HUVEC after 96 hrs by MTT assay
|
[PMID: 30248654]
|
HUVEC
|
IC50 |
7.8 μM
Compound: XL184; BMS-907351
|
Inhibition of VEGFR-2 phosphorylation in HUVEC incubated for 1 to 3 hrs
Inhibition of VEGFR-2 phosphorylation in HUVEC incubated for 1 to 3 hrs
|
[PMID: 26717201]
|
HUVEC
|
IC50 |
|
Antiproliferative activity against HUVEC cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Antiproliferative activity against HUVEC cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31382120]
|
L02
|
IC50 |
54.97 μM
Compound: 1; XL-184
|
Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33601310]
|
MCF7
|
IC50 |
0.45 μM
Compound: 1; XL-184
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33601310]
|
MCF7
|
IC50 |
14.26 μM
Compound: Cabozantinib
|
Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 34186178]
|
MCF7
|
IC50 |
2889 nM
Compound: Cabozantinib
|
Growth inhibition of human MCF7 cells incubated for 72 hrs by CCK8 assay
Growth inhibition of human MCF7 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 28651979]
|
MCF7
|
IC50 |
30.87 μM
Compound: XL-184
|
Antiproliferative activity against human MCF7 cells expressing c-Met after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells expressing c-Met after 48 hrs by MTT assay
|
[PMID: 35227978]
|
MCF7
|
IC50 |
5.4 μM
Compound: Cabozantinib
|
Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay
Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33045329]
|
MCF7
|
IC50 |
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 32738414]
|
MCF7
|
IC50 |
8.57 μM
Compound: Cabozantinib
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 30503936]
|
MDA-MB-231
|
IC50 |
13.4 μM
Compound: Cabozantinib
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 30503936]
|
MDA-MB-231
|
IC50 |
19.72 μM
Compound: Cabozantinib
|
Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 34186178]
|
MDA-MB-231
|
IC50 |
42 μM
Compound: XL184; BMS-907351
|
Inhibition of KIT (unknown origin) phosphorylation transfected in human MDA-MB-231 cells incubated for 1 to 3 hrs
Inhibition of KIT (unknown origin) phosphorylation transfected in human MDA-MB-231 cells incubated for 1 to 3 hrs
|
[PMID: 26717201]
|
MDA-MB-231
|
IC50 |
5 μM
Compound: XL184; BMS-907351
|
Inhibition of AXL phosphorylation in human MDA-MB-231 cells incubated for 1 to 3 hrs
Inhibition of AXL phosphorylation in human MDA-MB-231 cells incubated for 1 to 3 hrs
|
[PMID: 26717201]
|
MDA-MB-231
|
IC50 |
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31382120]
|
MKN-45
|
IC50 |
|
Antiproliferative activity against human MKN-45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MKN-45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32113049]
|
MKN-45
|
IC50 |
6.9 nM
Compound: Cabozantinib
|
Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
|
[PMID: 30248654]
|
MV4-11
|
IC50 |
15.16 μM
Compound: Cabozantinib
|
Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 31466809]
|
NCI-H1299
|
IC50 |
1919 nM
Compound: Cabozantinib
|
Growth inhibition of human H1299 cells incubated for 72 hrs by CCK8 assay
Growth inhibition of human H1299 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 28651979]
|
NCI-H1975
|
IC50 |
6.67 μM
Compound: Cabozantinib
|
Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31307762]
|
NCI-H292
|
IC50 |
≥ 50 nM
Compound: Cabozantinib
|
Antiproliferative activity against human NCI-H292 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H292 cells after 72 hrs by MTT assay
|
[PMID: 30248654]
|
NCI-H460
|
IC50 |
|
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32113049]
|
NCI-H460
|
IC50 |
40.1 nM
Compound: Cabozantinib
|
Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
|
[PMID: 30248654]
|
NCI-H460
|
IC50 |
5669 nM
Compound: Cabozantinib
|
Growth inhibition of human H460 cells incubated for 72 hrs by CCK8 assay
Growth inhibition of human H460 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 28651979]
|
NCI-H727
|
IC50 |
14010 nM
Compound: Cabozantinib
|
Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay
Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay
|
[PMID: 29057042]
|
NIH3T3
|
GI50 |
> 10 μM
Compound: Cabozantinib
|
Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
|
[PMID: 29133048]
|
NIH3T3
|
GI50 |
0.1 μM
Compound: Cabozantinib
|
Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
|
[PMID: 29133048]
|
PANC-1
|
IC50 |
5.13 μM
Compound: Cabozantinib
|
Cytotoxicity against human PANC-1 cells assessed as reduction cell viability by MTT assay
Cytotoxicity against human PANC-1 cells assessed as reduction cell viability by MTT assay
|
[PMID: 34175535]
|
PC-3
|
IC50 |
1.9 μM
Compound: XL184; BMS-907351
|
Inhibition of c-Met phosphorylation in human PC3 cells incubated for 1 to 3 hrs
Inhibition of c-Met phosphorylation in human PC3 cells incubated for 1 to 3 hrs
|
[PMID: 26717201]
|
PC-3
|
IC50 |
3.68 μM
Compound: Cabozantinib
|
Cytotoxicity against human PC-3 cells assessed as reduction cell viability by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction cell viability by MTT assay
|
[PMID: 34175535]
|
PC-3
|
IC50 |
8.25 μM
Compound: Cabozantinib
|
Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
|
[PMID: 31757525]
|
Sf21
|
IC50 |
|
Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay
Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay
|
[PMID: 26874741]
|
Sf21
|
IC50 |
3 nM
Compound: Cabozantinib
|
Inhibition of wild type N-terminal GST-tagged recombinant human RET (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
Inhibition of wild type N-terminal GST-tagged recombinant human RET (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
|
[PMID: 27131066]
|
Sf21
|
IC50 |
811 nM
Compound: Cabozantinib
|
Inhibition of N-terminal GST-tagged recombinant human RET V804M mutant (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
Inhibition of N-terminal GST-tagged recombinant human RET V804M mutant (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
|
[PMID: 27131066]
|
SiHa
|
IC50 |
|
Antiproliferative activity against human SiHa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Antiproliferative activity against human SiHa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31382120]
|
SNU-5
|
IC50 |
12.1 nM
Compound: Cabozantinib
|
Antiproliferative activity against human SNU5 cells after 72 hrs by MTT assay
Antiproliferative activity against human SNU5 cells after 72 hrs by MTT assay
|
[PMID: 30248654]
|
SW-620
|
IC50 |
3.37 μM
Compound: Cabozantinib
|
Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31307762]
|
T47D
|
IC50 |
4448 nM
Compound: Cabozantinib
|
Growth inhibition of human T47D cells incubated for 72 hrs by CCK8 assay
Growth inhibition of human T47D cells incubated for 72 hrs by CCK8 assay
|
[PMID: 28651979]
|
T47D
|
IC50 |
|
Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31382120]
|
TT
|
GI50 |
0.12 μM
Compound: Cabozantinib
|
Inhibition of RET C634W mutant in human TT cells assessed as cell growth inhibition after 10 days by MTT assay
Inhibition of RET C634W mutant in human TT cells assessed as cell growth inhibition after 10 days by MTT assay
|
[PMID: 26652860]
|